BioOutsource and Cellca are now Sartorius Stedim Biotech

We are proud to announce BioOutsource and Cellca are now Sartorius Stedim Biotech providing a fully integrated cell line and upstream development service.

Sartorius Stedim Biotech, a leading supplier of products and services for the biopharmaceutical industry, acquired BioOutsource and Cellca to further expand their portfolio of innovative drug development services.

BioOutsource and Cellca provide a fully integrated portfolio of services to provide a total solution for biopharmaceutical drug development; BioOutsource are global leaders in contract testing & research services, and Cellca a leading provider of cell line development & upstream process. The joint business offering provides a total solution to support drug development, from early stage cell line development, GMP cell bank manufacture & characterization, analytical testing from clone selection, process development, characterization through to GMP lot release. Committed to offering a first class service package, Sartorius Stedim Biotech are consistently developing technology with their in-house R&D departments to expand their extensive technical expertise to address market demands.

Learn more about our expertise and service offering.

Learn more

Sartorius Stedim Biotech – Upstream Development Services Locations

Glasgow, UK – BioOutsource Contract Testing Services & Cell Bank Manufacture

Laupheim, Germany – Cellca Cell Line Development & Upstream Process

Cambridge, USA  – North America Bioanalytical and Biosafety Testing Services

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

* you agree to receive emails with tips, news, insights and quizzes.